PT2874630T - Regime de dosagem para inibidores de janus quinase (jak) - Google Patents

Regime de dosagem para inibidores de janus quinase (jak)

Info

Publication number
PT2874630T
PT2874630T PT13742573T PT13742573T PT2874630T PT 2874630 T PT2874630 T PT 2874630T PT 13742573 T PT13742573 T PT 13742573T PT 13742573 T PT13742573 T PT 13742573T PT 2874630 T PT2874630 T PT 2874630T
Authority
PT
Portugal
Prior art keywords
jak
inhibitors
dosing regimen
janus kinase
janus
Prior art date
Application number
PT13742573T
Other languages
English (en)
Inventor
J Gonzales Andrea
B Cosgrove Sallie
B Malpas Phyllis
Rolf Stegemann Michael
Turner Collard Wendy
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2874630(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PT2874630T publication Critical patent/PT2874630T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PT13742573T 2012-07-20 2013-07-18 Regime de dosagem para inibidores de janus quinase (jak) PT2874630T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25

Publications (1)

Publication Number Publication Date
PT2874630T true PT2874630T (pt) 2019-01-31

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13742573T PT2874630T (pt) 2012-07-20 2013-07-18 Regime de dosagem para inibidores de janus quinase (jak)

Country Status (24)

Country Link
US (1) US9522151B2 (pt)
EP (1) EP2874630B1 (pt)
JP (2) JP6022063B2 (pt)
KR (2) KR20150028299A (pt)
CN (2) CN104470525A (pt)
AU (1) AU2013292547B2 (pt)
BR (1) BR112015000808A2 (pt)
CA (1) CA2878867C (pt)
CY (1) CY1121436T1 (pt)
DK (1) DK2874630T3 (pt)
ES (1) ES2707627T3 (pt)
HK (2) HK1209314A1 (pt)
HR (1) HRP20182088T1 (pt)
HU (1) HUE042771T2 (pt)
IN (1) IN2015DN00370A (pt)
LT (1) LT2874630T (pt)
MX (1) MX360857B (pt)
NZ (1) NZ703152A (pt)
PL (1) PL2874630T3 (pt)
PT (1) PT2874630T (pt)
RS (1) RS58242B1 (pt)
SI (1) SI2874630T1 (pt)
WO (1) WO2014015107A1 (pt)
ZA (1) ZA201500134B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6145179B2 (ja) 2013-02-22 2017-06-07 ファイザー・インク ヤヌス関連キナーゼ(JAK)の阻害剤としてのピロロ[2,3−d]ピリミジン誘導体
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
WO2017143014A1 (en) * 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
PL3915989T3 (pl) * 2019-01-30 2023-12-11 Felicamed Biotechnology Co., Ltd Inhibitor jak i sposób jego otrzymywania
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
US11827657B2 (en) 2020-12-18 2023-11-28 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1128800C (zh) * 1998-06-19 2003-11-26 辉瑞产品公司 吡咯并[2,3-d]嘧啶化合物及其组合物和用途
PL2384326T3 (pl) * 2008-08-20 2014-09-30 Zoetis Services Llc Związki pirolo[2,3-d]pirymidyonowe

Also Published As

Publication number Publication date
SI2874630T1 (sl) 2019-04-30
CY1121436T1 (el) 2020-05-29
JP6022063B2 (ja) 2016-11-09
HK1252083A1 (zh) 2019-05-17
PL2874630T3 (pl) 2019-04-30
EP2874630A1 (en) 2015-05-27
US9522151B2 (en) 2016-12-20
EP2874630B1 (en) 2018-12-05
MX2015000871A (es) 2015-05-07
CA2878867A1 (en) 2014-01-23
HK1209314A1 (en) 2016-04-01
BR112015000808A2 (pt) 2017-06-27
MX360857B (es) 2018-11-20
NZ703152A (en) 2016-03-31
CN104470525A (zh) 2015-03-25
CA2878867C (en) 2018-01-09
LT2874630T (lt) 2019-02-11
DK2874630T3 (en) 2019-01-28
CN108354938A (zh) 2018-08-03
AU2013292547B2 (en) 2017-05-04
ZA201500134B (en) 2016-08-31
JP2015522620A (ja) 2015-08-06
KR20150028299A (ko) 2015-03-13
JP2017019816A (ja) 2017-01-26
RS58242B1 (sr) 2019-03-29
KR20170034949A (ko) 2017-03-29
AU2013292547A1 (en) 2015-01-22
US20150126535A1 (en) 2015-05-07
WO2014015107A1 (en) 2014-01-23
HUE042771T2 (hu) 2019-07-29
HRP20182088T1 (hr) 2019-02-08
ES2707627T3 (es) 2019-04-04
IN2015DN00370A (pt) 2015-06-12

Similar Documents

Publication Publication Date Title
HK1254429A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
HRP20182088T1 (hr) Režim doziranja za inhibitore janus kinaze (jak)
HK1212683A1 (zh) 多個激酶途徑抑制劑
HK1200828A1 (en) Kinase inhibitors
EP2758051A4 (en) CYANOMETHYLPYRAZOLCARBOXAMIDES AS JANUS KINASEINHIBITORS
HUE048834T2 (hu) Kináz inhibitorok
HK1211574A1 (en) Serine threonine kinase inhibitors
HK1209277A1 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6-
PL2634185T3 (pl) Inhibitory kinazy TYK2
IL229028A0 (en) Kinase inhibitors
HK1199873A1 (en) Kinase inhibitors
HK1213252A1 (zh) 雙環二氫吡啶酮激酶抑制劑
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1213181A1 (zh) 雙環氧雜內酰胺激酶抑制劑